Matrix Asset Advisors Position in Thermo Fisher Scientific (TMO) Has Trimmed by $1.83 Million; As Amgen (AMGN) Share Value Declined, Capital Management Has Cut Stake

Thermo Fisher Scientific Inc. (NYSE:TMO) Logo

Capital Management Corp decreased its stake in Amgen Inc (AMGN) by 8.47% based on its latest 2018Q3 regulatory filing with the SEC. Capital Management Corp sold 2,840 shares as the company’s stock declined 4.15% with the market. The institutional investor held 30,700 shares of the biological products (no diagnostic substances) company at the end of 2018Q3, valued at $6.36 million, down from 33,540 at the end of the previous reported quarter. Capital Management Corp who had been investing in Amgen Inc for a number of months, seems to be less bullish one the $127.80 billion market cap company. The stock decreased 1.05% or $2.12 during the last trading session, reaching $200.56. About 3.38M shares traded or 10.37% up from the average. Amgen Inc. (NASDAQ:AMGN) has risen 11.57% since January 12, 2018 and is uptrending. It has outperformed by 11.57% the S&P500. Some Historical AMGN News: 22/05/2018 – AMGEN INC – BRIAN J. DRUKER, A NEW NOMINEE FOR DIRECTOR, WAS ALSO ELECTED; 17/05/2018 – FDA GRANTED APPROVAL OF AIMOVIG TO AMGEN; 26/03/2018 – COHERUS: DISTRICT CRT ACCEPTS RECOMMENDED AMGEN SUIT DISMISSAL; 23/03/2018 – AMGEN INC – CHMP POSITIVE OPINION FOR ABP 980 WILL NOW BE REVIEWED BY EUROPEAN COMMISSION; 18/04/2018 – #2 Blockbuster ambitions: Amgen/Novartis team lines up more promising PhIII erenumab data for some of the toughest migraine patients $AMGN $NVS; 03/04/2018 – Amgen Inc. | anti-EGFRvIII x anti-CD3 bispecific T cell engager antibody construct | N/A | 04/02/2018 | Treatment of glioblastoma | Designated | NFDA | N/A | | N/A; 29/03/2018 – FDA SAYS GRANTED APPROVAL OF BLINCYTO TO AMGEN; 08/03/2018 – AMGEN REPORTS FINAL RESULTS OF TENDER OFFER; 17/05/2018 – Amgen and Novartis: Expect Approval in the EU in the Coming Months; 18/05/2018 – Novartis, Amgen: Aimovig Is Migraine Prevention Drug

Matrix Asset Advisors Inc decreased its stake in Thermo Fisher Scientific Inc (TMO) by 12.41% based on its latest 2018Q3 regulatory filing with the SEC. Matrix Asset Advisors Inc sold 7,502 shares as the company’s stock declined 0.05% with the market. The institutional investor held 52,929 shares of the industrial machinery and components company at the end of 2018Q3, valued at $12.92 million, down from 60,431 at the end of the previous reported quarter. Matrix Asset Advisors Inc who had been investing in Thermo Fisher Scientific Inc for a number of months, seems to be less bullish one the $96.62 billion market cap company. The stock increased 0.48% or $1.14 during the last trading session, reaching $240. About 1.37 million shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 27.72% since January 12, 2018 and is uptrending. It has outperformed by 27.72% the S&P500. Some Historical TMO News: 30/04/2018 – Mudrick Capital: Opposes Globalstar Inc.’s Proposed Merger Deal With Thermo Acquisitions Subsidiary; 25/04/2018 – Thermo Fisher Sees FY Rev $23.62B-$23.86B; 29/05/2018 – VIKRAM THERMO (INDIA) LTD VKMT.BO SAYS CO RECOMMENDED DIVIDEND AT 5 PCT; 16/04/2018 – Thermo Fisher Scientific Launches Oncomine Childhood Cancer Research Assay and Establishes International Childhood Oncology Net; 16/03/2018 – Thermo Fisher Closes Below 50-Day Moving Average: Technicals; 01/05/2018 – Thermo Fisher Will Retain Global Commercialization Rights for Oncomine Dx Target Test; 03/04/2018 – TMO:RAPID MYCOPLASMA TEST METHOD ACCEPTED FOR QA/QC,LOT RELEASE; 09/03/2018 – Skyland Analytics Appoints James C. Mullen, Former Biogen and Patheon CEO, to Advisory Board; 15/05/2018 – Thermo Fisher Presenting at Bank of America Conference Tomorrow; 23/05/2018 – TMO ON TRACK TO EXCEED $80M TOTAL SYNERGY TARGET BY 2019:SLIDES

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on February, 7. They expect $3.25 earnings per share, up 12.46% or $0.36 from last year’s $2.89 per share. AMGN’s profit will be $2.07 billion for 15.43 P/E if the $3.25 EPS becomes a reality. After $3.69 actual earnings per share reported by Amgen Inc. for the previous quarter, Wall Street now forecasts -11.92% negative EPS growth.

Among 27 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 16 Hold. Therefore 41% are positive. Amgen Inc. had 101 analyst reports since August 3, 2015 according to SRatingsIntel. Oppenheimer maintained Amgen Inc. (NASDAQ:AMGN) on Friday, July 21 with “Buy” rating. Morgan Stanley upgraded the stock to “Overweight” rating in Tuesday, December 15 report. Piper Jaffray maintained it with “Overweight” rating and $200 target in Saturday, August 29 report. The firm has “Overweight” rating given on Thursday, October 11 by Morgan Stanley. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Overweight” rating by PiperJaffray on Friday, February 2. JP Morgan maintained it with “Neutral” rating and $192 target in Friday, July 27 report. Morgan Stanley maintained Amgen Inc. (NASDAQ:AMGN) on Friday, July 13 with “Overweight” rating. Oppenheimer maintained the shares of AMGN in report on Tuesday, August 29 with “Buy” rating. As per Wednesday, February 1, the company rating was upgraded by Bank of America. Oppenheimer maintained the stock with “Buy” rating in Monday, June 5 report.

Capital Management Corp, which manages about $401.58M and $391.43M US Long portfolio, upped its stake in Fastenal Co (NASDAQ:FAST) by 72,990 shares to 260,816 shares, valued at $15.13M in 2018Q3, according to the filing. It also increased its holding in Prudential Finl Inc (NYSE:PRU) by 8,695 shares in the quarter, for a total of 87,644 shares, and has risen its stake in Bristol Myers Squibb Co (NYSE:BMY).

More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: Seekingalpha.com which released: “Amgen and UCB’s Evenity OK’d in Japan for osteoporosis – Seeking Alpha” on January 08, 2019, also Nasdaq.com with their article: “Health Care Sector Update for 12/24/2018: ACOR, CDXC, RDY, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” published on December 24, 2018, Seekingalpha.com published: “Amgen submits U.S. marketing application for Remicade biosimilar – Seeking Alpha” on December 17, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: Streetinsider.com and their article: “Amgen (AMGN) Announces Plan to Make All Repatha Device Options Available In US at 60 Percent Reduced List Price – StreetInsider.com” published on January 07, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 01/04/2019: FLKS, NVAX, ESPR, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” with publication date: January 04, 2019.

Investors sentiment decreased to 0.87 in Q3 2018. Its down 0.12, from 0.99 in 2018Q2. It worsened, as 49 investors sold AMGN shares while 550 reduced holdings. 130 funds opened positions while 393 raised stakes. 470.42 million shares or 2.68% less from 483.36 million shares in 2018Q2 were reported. Raab And Moskowitz Asset Limited Co invested 0.04% in Amgen Inc. (NASDAQ:AMGN). Massachusetts-based Rosenbaum Jay D has invested 3.62% in Amgen Inc. (NASDAQ:AMGN). Caprock stated it has 6,151 shares. Pennsylvania Co has invested 0.86% in Amgen Inc. (NASDAQ:AMGN). 532,163 are owned by Stifel Corp. Altfest L J And Co invested 0.3% in Amgen Inc. (NASDAQ:AMGN). Capital Research Global Investors owns 34.42 million shares. Moreover, Principal Financial Group Inc has 0.23% invested in Amgen Inc. (NASDAQ:AMGN) for 1.23 million shares. Williams Jones And Associate Limited Liability Co holds 0.27% or 65,462 shares in its portfolio. Texas Yale holds 8,401 shares. Groesbeck Inv Nj holds 19,201 shares. Moreover, National Bank Of Hawaii has 0.24% invested in Amgen Inc. (NASDAQ:AMGN) for 14,915 shares. Old Second National Bank Of Aurora reported 234 shares or 0.02% of all its holdings. Toth Fincl Advisory Corporation holds 0.63% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 13,648 shares. Aull And Monroe Investment stated it has 1.53% in Amgen Inc. (NASDAQ:AMGN).

Since November 29, 2018, it had 0 insider buys, and 2 selling transactions for $4.27 million activity. 20,000 Amgen Inc. (NASDAQ:AMGN) shares with value of $3.91M were sold by Jacks Tyler.

Among 20 analysts covering Thermo Fisher Scientific (NYSE:TMO), 17 have Buy rating, 0 Sell and 3 Hold. Therefore 85% are positive. Thermo Fisher Scientific had 74 analyst reports since July 24, 2015 according to SRatingsIntel. The company was initiated on Tuesday, October 6 by Argus Research. Barclays Capital maintained it with “Buy” rating and $215.0 target in Monday, September 25 report. The firm has “Outperform” rating by Leerink Swann given on Monday, October 9. As per Wednesday, September 27, the company rating was maintained by Jefferies. Morgan Stanley maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Thursday, July 26. Morgan Stanley has “Overweight” rating and $242 target. On Friday, April 29 the stock rating was downgraded by Jefferies to “Hold”. The company was maintained on Thursday, February 1 by Morgan Stanley. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Overweight” rating by Morgan Stanley on Thursday, April 26. BTIG Research reinitiated the shares of TMO in report on Friday, July 22 with “Buy” rating. Leerink Swann maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Friday, April 28. Leerink Swann has “Buy” rating and $187 target.

Since October 1, 2018, it had 0 insider purchases, and 5 selling transactions for $39.04 million activity. CASPER MARC N had sold 125,520 shares worth $31.07M on Monday, October 1. On Thursday, November 29 the insider Herrema Gregory J. sold $4.26 million. Williamson Stephen also sold $2.29M worth of Thermo Fisher Scientific Inc. (NYSE:TMO) shares.

Analysts await Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings on January, 30 before the open. They expect $3.19 EPS, up 14.34% or $0.40 from last year’s $2.79 per share. TMO’s profit will be $1.28B for 18.81 P/E if the $3.19 EPS becomes a reality. After $2.62 actual EPS reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts 21.76% EPS growth.

Matrix Asset Advisors Inc, which manages about $977.80 million and $626.90M US Long portfolio, upped its stake in Bb&T Corp (NYSE:BBT) by 18,974 shares to 339,247 shares, valued at $16.47M in 2018Q3, according to the filing. It also increased its holding in Goldman Sachs Group Inc (NYSE:GS) by 2,782 shares in the quarter, for a total of 46,160 shares, and has risen its stake in State Str Corp (NYSE:STT).

More notable recent Thermo Fisher Scientific Inc. (NYSE:TMO) news were published by: Investorplace.com which released: “The 7 Best Companies With Large Stock Buybacks – Investorplace.com” on September 25, 2018, also Seekingalpha.com with their article: “Thermo Fisher Scientific (TMO) Presents At 36th Annual J.P. Morgan Healthcare Conference – Slideshow – Seeking Alpha” published on January 10, 2018, Seekingalpha.com published: “Thermo Fisher to buy back $2B of stock – Seeking Alpha” on September 07, 2018. More interesting news about Thermo Fisher Scientific Inc. (NYSE:TMO) were released by: Seekingalpha.com and their article: “Thermo Fisher CE marks Oncomine Dx target test – Seeking Alpha” published on October 17, 2018 as well as Streetinsider.com‘s news article titled: “Thermo Fisher Scientific (TMO) Reports Acquisition of Advanced Bioprocessing Business from Becton, Dickinson and Company (BDX) – StreetInsider.com” with publication date: September 07, 2018.

Investors sentiment decreased to 0.85 in 2018 Q3. Its down 0.23, from 1.08 in 2018Q2. It is negative, as 41 investors sold TMO shares while 434 reduced holdings. 111 funds opened positions while 295 raised stakes. 333.46 million shares or 0.38% more from 332.19 million shares in 2018Q2 were reported. Girard Partners Ltd owns 19,079 shares or 0.83% of their US portfolio. Svcs has invested 0.19% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Sound Shore Management Inc Ct invested in 2.82% or 674,710 shares. Spinnaker has invested 0.08% in Thermo Fisher Scientific Inc. (NYSE:TMO). Mariner Limited Liability Co holds 0.26% or 41,488 shares. Moors & Cabot holds 0.12% or 3,893 shares. The New Jersey-based Palisade Cap Mgmt Nj has invested 0.03% in Thermo Fisher Scientific Inc. (NYSE:TMO). Ls Inv Ltd Llc owns 7,844 shares or 0.11% of their US portfolio. Heritage Wealth Advsrs has 1,184 shares. Grisanti Mngmt Limited holds 2.87% or 23,893 shares. Fdx Advsr Incorporated accumulated 0.06% or 6,089 shares. Toronto Dominion Bank holds 282,283 shares or 0.13% of its portfolio. Hudson Bay Cap Management Limited Partnership holds 175,720 shares or 0.53% of its portfolio. Sit Investment Incorporated owns 36,585 shares. Bluestein R H &, a Michigan-based fund reported 1,752 shares.

Thermo Fisher Scientific Inc. (NYSE:TMO) Institutional Positions Chart